Author

Camilla Johansson

AstraZeneca (Sweden)Primary ORCID profile (0000-0002-2685-5715 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Camilla JohanssoniD1 paper · Uppsala University

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:CRISPR screen· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Organism:mouse· 1 Research Focus:variant calling· 1

Frequent Co-Authors

Abdel Wahad Bidar· 1 shared Amir Taheri‐GhahfarokhiiD· 1 shared Anders LundiniD· 1 shared Anna Schantz· 1 shared Babak Alaei-MahabadiiD· 1 shared Carla P. MartinsiD· 1 shared Elizabeth L. Hardaker· 1 shared Emma Jane DaviesiD· 1 shared

Activity by Year

2020-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperGenomics

Abdel Wahad Bidar

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

ObLiGaRe doxycycline Inducible (ODIn) Cas9 system driving pre-clinical drug discovery, from design to cancer treatment

Anders Lundin, Michelle J. Porritt, Himjyot Jaiswal, Frank Seeliger, Camilla Johansson, Abdel Wahad Bidar, Lukas Badertscher, Emma Jane Davies, Elizabeth L. Hardaker, Carla P. Martins, Therése Admyre, Amir Taheri‐Ghahfarokhi, Jenna Bradley, Anna Schantz, Babak Alaei-Mahabadi, , Marcello Maresca

This paper introduces an inducible CRISPR-Cas9 system for preclinical drug discovery, enabling controlled genome editing in mice to model cancer and test therapies.

bioRxiv · Apr 6, 2020 · PreprintGenomics